ATE533509T1 - Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff - Google Patents

Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff

Info

Publication number
ATE533509T1
ATE533509T1 AT04771640T AT04771640T ATE533509T1 AT E533509 T1 ATE533509 T1 AT E533509T1 AT 04771640 T AT04771640 T AT 04771640T AT 04771640 T AT04771640 T AT 04771640T AT E533509 T1 ATE533509 T1 AT E533509T1
Authority
AT
Austria
Prior art keywords
short
heart
blockers
active ingredients
blocker
Prior art date
Application number
AT04771640T
Other languages
English (en)
Inventor
Masaharu Hirano
Kenzo Nakao
Ken Mizushima
Morito Akisada
Takahiro Azuma
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34131580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE533509(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE533509T1 publication Critical patent/ATE533509T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04771640T 2003-08-08 2004-08-06 Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff ATE533509T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003290301 2003-08-08
PCT/JP2004/011672 WO2005014042A1 (ja) 2003-08-08 2004-08-06 短時間型β遮断薬を有効成分とする心拍数減少剤

Publications (1)

Publication Number Publication Date
ATE533509T1 true ATE533509T1 (de) 2011-12-15

Family

ID=34131580

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04771640T ATE533509T1 (de) 2003-08-08 2004-08-06 Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff

Country Status (6)

Country Link
US (2) US20060286037A1 (de)
EP (1) EP1652533B2 (de)
JP (2) JP4816083B2 (de)
AT (1) ATE533509T1 (de)
ES (1) ES2374199T5 (de)
WO (1) WO2005014042A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE533509T1 (de) † 2003-08-08 2011-12-15 Ono Pharmaceutical Co Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
KR101516452B1 (ko) * 2007-08-24 2015-04-30 오노 야꾸힝 고교 가부시키가이샤 관동맥의 묘출능 개선제
US20100056825A1 (en) * 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
US8324426B2 (en) * 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation
FR2938194B1 (fr) 2008-11-07 2012-08-31 Servier Lab Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe
US8611989B2 (en) * 2010-11-30 2013-12-17 Kabushiki Kaisha Toshiba Multi-planar reconstruction lumen imaging method and apparatus
AU2012211318C1 (en) * 2011-01-27 2016-08-04 Baxter Healthcare S.A. Methods of treating tachycardia and/or controlling heart rate while minimizing and/or controlling hypotension
CN103347513A (zh) 2011-01-27 2013-10-09 巴克斯特国际公司 (s)-艾司洛尔用于控制与心脏病治疗相关的静脉刺激的应用
EP2796139A1 (de) 2013-04-26 2014-10-29 AOP Orphan Pharmaceuticals AG Verwendung von Landiololhydrochlorid bei der Langzeitbehandlung von Tachyarrhythmien
CN106265539A (zh) * 2016-08-31 2017-01-04 辰欣药业股份有限公司 一种盐酸兰地洛尔冻干粉针剂及其制备工艺
WO2025153663A1 (en) 2024-01-17 2025-07-24 Aop Orphan Pharmaceuticals Gmbh Complexed landiolol encapsulated or dissolved in lipophilic matrix
CN118975994B (zh) * 2024-08-26 2025-10-28 北京阳光诺和药物研究股份有限公司 一种注射用β-阻滞剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4387103A (en) * 1980-11-28 1983-06-07 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
JPH024651A (ja) 1988-06-14 1990-01-09 Asahi Kasei Porifuretsukusu Kk スタンドパック及びその製法
CA2015730C (en) 1989-05-12 1997-10-07 Sadahiko Iguchi Esters of phenylalkanoic acid
JP3302647B2 (ja) 1992-04-24 2002-07-15 小野薬品工業株式会社 フェニルアルカン酸エステルの塩酸塩、およびその製造方法
SE9401174D0 (sv) * 1994-04-07 1994-04-07 Astra Ab New combination
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE533509T1 (de) † 2003-08-08 2011-12-15 Ono Pharmaceutical Co Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff

Also Published As

Publication number Publication date
WO2005014042A1 (ja) 2005-02-17
JP2011084583A (ja) 2011-04-28
JPWO2005014042A1 (ja) 2006-09-28
EP1652533A1 (de) 2006-05-03
ES2374199T5 (es) 2015-01-13
EP1652533B1 (de) 2011-11-16
US20060286037A1 (en) 2006-12-21
EP1652533A4 (de) 2009-11-04
ES2374199T3 (es) 2012-02-14
JP4816083B2 (ja) 2011-11-16
EP1652533B2 (de) 2014-11-19
US20120184545A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
WO2004002999A3 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
WO2006133941A3 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
EP2087891A3 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Lymphom
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
EP1783126A3 (de) N-Oxide von N-Phenyl-2-Pyrimidinamin Derivaten
DE60100994D1 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
EP1652533A4 (de) Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff
CA2580448A1 (en) Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
CA2360451A1 (en) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
SE9901573D0 (sv) New compounds
WO2006078277A3 (en) Dalbavancin compositions for treatment of bacterial infections
EP4696379A3 (de) Hybride amidderivate von amphotericin b
WO2004048328A3 (en) N-arylsulfonyl-3-aminoalkoxyindoles
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
SI1610787T1 (sl) Sinergistična kombinacija, ki obsega roflumilastin antiholinergično sredstvo, izbrano izmed tiotropijevih soli, za zdravljenje respiratornih bolezni
WO2007030944A3 (en) Methods of cardioprotection using dichloroacetate in combination with an inotrope
JP2002542281A5 (de)
SE0002729D0 (sv) Novel compound form
TW200616644A (en) Medicine for prevention or treatment of diabetes
NO20060651L (no) Fremgangsmate for behandling av virale infeksjoner
MXPA05010161A (es) Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
SE9901572D0 (sv) New compounds
WO2003026570A3 (en) Reduced toxicity cisplatin formulations and methods for using the same